Core Insights - Zymeworks Inc. presented six posters at the AACR Annual Meeting, showcasing advancements in their antibody-drug conjugate and T cell engager platforms, particularly highlighting the promising preclinical data for ZW209 in small cell lung cancer [1][2]. T Cell Engagers (TCE) - ZW209, a DLL3-targeted trispecific T cell engager, shows safety and potent preclinical efficacy in small cell lung cancer models, with an IND submission expected in the first half of 2026 [4][8]. - ZW171, a bispecific antibody targeting mesothelin, demonstrates anti-tumor activity across various cancers, including ovarian and pancreatic cancers, and is currently in a global Phase 1 clinical study [3][5]. Antibody-Drug Conjugates (ADCs) - ZW327, a novel Ly6E-targeting ADC, exhibits significant in vitro cytotoxicity against multiple tumor types, including breast and lung cancers, and shows robust anti-tumor activity in xenograft models [6][9]. - A biparatopic ADC targeting protein tyrosine kinase 7 (PTK7) has been developed, demonstrating improved binding and internalization compared to previous ADCs, with promising results in breast and lung cancer models [7][10]. Preclinical Development and Technologies - Zymeworks has developed high-throughput functional screening methods in 3D tumor models to enhance the evaluation of ADCs during preclinical development [11]. - In vitro assays have been created to predict ADC hematological toxicity, which could improve the selection of optimal linkers and payloads in ADC development [12][16]. Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for challenging diseases, including cancer and autoimmune conditions, leveraging its proprietary technologies [14][17].

Core Viewpoint - Zymeworks Inc. has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development, enhancing its leadership team to advance its clinical-stage oncology portfolio and diversify into autoimmune and inflammatory diseases [1][2]. Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune diseases [1][4]. - The company utilizes proprietary technologies to engineer and develop differentiated antibody-based therapeutic candidates, including zanidatamab, a HER2-targeted bispecific antibody [4][5]. Leadership Changes - Dr. Sabeen Mekan, with 18 years of experience in hematology and oncology, will play a crucial role in formulating the clinical development strategy for Zymeworks' oncology portfolio [2][3]. - Dr. Jeff Smith continues as Executive Vice President & Chief Medical Officer, focusing on R&D in autoimmune and inflammatory diseases [1][2]. - Barbara Schaeffler has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith [1]. Clinical Development Focus - The expanded clinical development team aims to enhance the focus on progressing Zymeworks' clinical-stage solid tumor portfolio while diversifying into autoimmune and inflammatory diseases [2]. - Dr. Mekan expressed commitment to addressing unmet needs in various cancer types through next-generation antibody-drug conjugates and multispecific antibody therapeutics [2][3]. Pipeline and Regulatory Progress - Zymeworks has received FDA accelerated approval for Ziihera® (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer [4]. - The company is advancing a robust pipeline, with Phase 1 studies for ZW171 and ZW191 actively recruiting and an investigational new drug application for ZW251 planned for mid-2025 [5].

Core Viewpoint - Zymeworks Inc. is set to report its first quarter 2025 financial results on May 8, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update [1][2] Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving treatment for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases [3] - The company utilizes its proprietary Azymetric™ technology to engineer and develop zanidatamab, a HER2-targeted bispecific antibody [3] - Zymeworks has exclusive agreements with BeiGene and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in different regions [3] - The U.S. FDA has granted accelerated approval for Ziihera® (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive second-line biliary tract cancer, marking it as the first dual HER2-targeted bispecific antibody approved for this indication in the U.S. [3] - Zanidatamab is currently under regulatory review in the EU and China and is being evaluated in multiple global clinical trials for various HER2-expressing cancers [3] - Zymeworks is advancing a robust pipeline of product candidates, with ongoing Phase 1 studies for ZW171 and ZW191, and plans for an investigational new drug application for ZW251 in mid-2025 [3] - The company has established strategic partnerships with global biopharmaceutical companies to further leverage its therapeutic platforms [3]

Core Viewpoint - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for challenging diseases, including cancer, inflammation, and autoimmune diseases, with an upcoming financial results announcement and corporate update scheduled for May 8, 2025 [1][2]. Company Overview - Zymeworks is dedicated to the discovery, development, and commercialization of multifunctional biotherapeutics, aiming to significantly impact the lives of patients with difficult-to-treat conditions [3]. - The company has developed zanidatamab, a HER2-targeted bispecific antibody utilizing proprietary Azymetric™ technology, and has secured exclusive development and commercialization agreements with BeiGene and Jazz Pharmaceuticals [3]. - Ziihera® (zanidatamab-hrii) has received accelerated approval from the U.S. FDA for treating adults with previously-treated, unresectable or metastatic HER2-positive second-line biliary tract cancer, marking it as the first dual HER2-targeted bispecific antibody approved for this indication in the U.S. [3]. - Zanidatamab is under regulatory review in the EU and China and is being evaluated in global clinical trials for various HER2-expressing cancers [3]. - Zymeworks is advancing a robust pipeline of product candidates, with ongoing Phase 1 studies for ZW171 and ZW191, and plans for an investigational new drug application for ZW251 in mid-2025 [3]. Upcoming Events - The company will report its first quarter 2025 financial results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time [1].

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve th ...

On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.Sales came at $31.03 million, missing the consensus of $45.2 million.In its fourth-quarter earnings results, Zymeworks said it is increasing its development efforts on plans for ZW251.“Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprior ...

Financial Data and Key Metrics Changes - Zymeworks reported a net loss of $122.7 million for the year ended December 31, 2024, compared to a net loss of $118.7 million in 2023, primarily due to a $17.3 million noncash impairment charge [14][16] - Revenue for 2024 was $76.3 million, slightly up from $76 million in 2023, including $25 million of milestone revenue from Jazz related to the FDA approval of Ziihera [14][15] - Operating expenses were $213.4 million for 2024, a slight decrease from $214.1 million in 2023, reflecting lower research and development expenses [15][16] Business Line Data and Key Metrics Changes - The company earned over $45 million from partnerships in the past year, with significant contributions from Jazz and BeiGene [10][12] - Ziihera achieved net product sales of $1.1 million in Q4 2024 following its launch, contributing to the company's revenue [11] Market Data and Key Metrics Changes - Zymeworks had approximately $324.2 million in cash resources as of December 31, 2024, down from $456.3 million in 2023, providing a cash runway into the second half of 2027 [21][22] Company Strategy and Development Direction - The company is focused on advancing its next-generation therapeutics, particularly in autoimmune and inflammatory diseases, as well as hematological oncology [9][12] - Zymeworks aims to leverage its innovative platforms to address emerging therapeutic challenges and expand its collaborations [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ZW251 for hepatocellular carcinoma and emphasized the importance of accelerating its clinical studies [46][47] - The company anticipates significant milestones in 2025, including top-line data from the HERIZON-GEA-01 study of zanidatamab [50] Other Important Information - The appointment of Oleg Nodelman to the Board reflects the growth of EcoR1's shareholding and confidence in Zymeworks' potential [48] - The company is exploring the potential of multi-payload ADCs and is investigating additional payloads for its products [120] Q&A Session Summary Question: On ZW251, will there be urgency to initiate combination cohorts? - Management confirmed that they are interested in early signs of tumor activity and will study ZW251 in both dose escalation and expansion cohorts [54][56] Question: What prompted the prioritization of ZW251 over ZW220? - The decision was based on excitement for ZW251 and the ability to accelerate its clinical studies, while still maintaining momentum for ZW171 and ZW191 [58][60] Question: What are the gating factors for filing the IND for ZW1528? - The company is focused on completing IND enabling activities and expects to provide realistic guidance for filing in the second half of 2026 [115][116] Question: Can you share thoughts on multi-payload ADCs? - Management indicated that they are investigating additional payloads and consider the therapeutic rationale important for developing such molecules [120] Question: What is the desired target product profile for ZW251? - The company aims to demonstrate efficacy across a broad range of hepatocellular carcinoma models and believes in the importance of the target in their design [128][129]

Zymeworks (ZYME) Q4 2024 Earnings Call March 06, 2025 03:33 AM ET Company Participants Shrinal Inamdar - Senior Director - IRLeone Patterson - Executive VP and Chief Business & Financial OfficerPaul Moore - Chief Scientific OfficerKenneth Galbraith - Chair and CEOManoj Eradath - Senior Biotechnology Equity ResearcherYigal Nochomovitz - DirectorJonathan Miller - Managing Director Conference Call Participants Stephen Willey - AnalystBrian Cheng - Biotech AnalystJay Olson - Managing Director & Senior Analyst - ...

Year End and 4Q 2024 Results Conference Call and Webcast March 5, 2025 Nasdaq: ZYME | zymeworks.com Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation and the accompanying oral commentary ...

Core Points - Zymeworks Inc. reported a quarterly loss of $0.31 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.32, but worse than the loss of $0.20 per share from the previous year, indicating a 55% increase in loss year-over-year [1] - The company posted revenues of $31.03 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 15.54%, and showing a significant increase from $16.93 million in the same quarter last year [2] - Zymeworks shares have declined approximately 12.9% since the beginning of the year, contrasting with the S&P 500's decline of 1.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.43 on revenues of $16.67 million, and for the current fiscal year, it is -$1.64 on revenues of $91.31 million [7] - The estimate revisions trend for Zymeworks is mixed, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]